This review aims to discuss the current treatment options available for genitourinary (GU) symptoms related to menopause in breast cancer (BC) survivors. 

The aim of this study was to evaluate the safety of giving stereotactic radiosurgery (SRS) at the same time as other cancer treatments for patients who have brain metastasis. The study found that SRS given in combination with chemotherapy, immunotherapy, or targeted therapy was safe with low levels of side effects.

This study compared the effectiveness of tocilizumab (Actemra) alone (monotherapy) to combination therapy with tocilizumab and methotrexate (Trexall) in patients with rheumatoid arthritis (RA).

The study concluded that combination treatment with tocilizumab and methotrexate may be more effective in slowing down signs of disease progression in joints.

This study looked at the association between breast cancer (BC) prognosis and statin use. The authors found that statin use is associated with a reduced recurrence and mortality in women with BC. 

This study investigated the relationship between the diagnosis of rheumatoid arthritis (RA) and the development of lung diseases (LDs) over five years. 

The study showed that the markers of RA activity were associated with the development of lung disease.

This study investigated the effect of disease-modifying anti-rheumatic drugs (DMARDs) on cardiovascular disease (CVD) risk.

They found that abatacept (Orencia) and tumor necrosis factor inhibitors (TNFi) were associated with decreased CVD risk.

This study reviewed infection risk in patients treated with biologic and targeted disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA).

This study was carried out to examine the effectiveness of olaparib (Lynparza) for the treatment of metastatic breast cancer (MBC; cancer that has spread) with gene mutations (abnormalities). The authors found that this treatment was effective for patients with MBC with BRCA1/2 mutations.

This study investigated the effect of baricitinib (Olumiant) on biomarkers in the blood, which indicate a state of joint destruction in patients with moderate to severe rheumatoid arthritis (RA).

The study showed that baricitinib reduced these biomarkers and resulted in decreased RA symptoms.

This study compared the safety of two hormonal medications used to treat breast cancer, tamoxifen (Nolvadex) and letrozole (Femara). This study found that tamoxifen was associated with an increased risk of blood clots, while letrozole was associated with an increased risk of angina and heart attacks.